Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 6 · below the Ichimoku cloud · RSI 31 · MACD below its signal · 5% above its 52-week low
| 50.70 | 52-week high | +1919.92% |
| 7.15 | Previous month high | +184.86% |
| 6.30 | Previous week high | +151.00% |
| 4.00 | Previous month low | +59.36% |
| 3.50 | Previous week low | +39.44% |
| 3.02 | R3 (classic) | +20.19% |
| 2.86 | R2 (classic) | +14.08% |
| 2.71 | Previous day high | +7.97% |
| 2.69 | R1 (classic) | +7.04% |
| 2.53 | Pivot | +0.93% |
| 2.51 | Price now | |
| 2.38 | Previous day low | −5.18% |
| 2.38 | 52-week low | −5.18% |
| 2.36 | S1 (classic) | −6.11% |
| 2.20 | S2 (classic) | −12.22% |
| 2.03 | S3 (classic) | −19.26% |
None of the 29 investors followed here reported a position in NXL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NXL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2025 | Osser Leonard ABeneficial Owner of more than 10% of a Class of Security | — | 83.3K | — |
| Sep 28, 2025 | Hu BenjaminDirector | — | 36.5K | — |
| Sep 28, 2025 | Owens DavidOfficer and Director | — | 36.5K | — |
| Sep 28, 2025 | Kazden AlanDirector | — | 36.5K | — |
| Mar 11, 2025 | Shelton Carolyn HambyOfficer | Purchase at price 2.20 per share. | 6K | $13.20K |
| Feb 3, 2025 | Owens DavidOfficer and Director | Purchase at price 2.98 per share. | 1K | $2.98K |
| Feb 3, 2025 | Owens DavidOfficer and Director | Purchase at price 3.10 per share. | 1K | $3.10K |
| Jan 27, 2025 | Owens DavidOfficer and Director | Purchase at price 2.70 per share. | 1.5K | $4.05K |
| Jan 22, 2025 | Owens DavidOfficer and Director | Purchase at price 2.50 - 2.70 per share. | 3K | $7.70K |
| Dec 19, 2024 | Owens DavidOfficer and Director | Purchase at price 2.75 per share. | 1K | $2.75K |
| Oct 27, 2024 | Owens DavidOfficer and Director | Purchase at price 2.19 per share. | 500 | $1.09K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.2 | -17.5 | -26.0 | 2.0 | 71.8 | -45.9 | 2.4 | -28.7 | -40.8 | -41.4 | −85.0% | ||
| 2025 | 5.8 | -7.2 | -28.0 | -6.7 | -34.6 | -17.0 | 1.2 | -4.4 | -4.1 | 63.6 | -28.0 | -48.3 | −79.8% |
| 2024 | -13.6 | -11.4 | 351.6 | 9.3 | -54.2 | 141.4 | -32.0 | -19.9 | -27.4 | 272.2 | 67.9 | -34.0 | +581.5% |
| 2023 | 41.5 | -16.0 | -10.1 | 2.5 | 4.9 | 4.0 | -9.4 | -44.9 | -1.3 | -34.1 | 34.5 | 3.8 | −45.9% |
| 2022 | 36.1 | 59.2 | -68.0 | −30.6% |
Buy / hold / sell counts
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.